---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-027933"
form_type: "8-K"
ticker: null
cik: "0001773427"
company_name: "SpringWorks Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:26:57.200572+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SpringWorks enters up to $250M ATM equity offering program with Cowen

## Summary
- Sales Agreement with Cowen and Company allows sales of common stock up to $250 million aggregate offering price.
- Shares sold through Nasdaq or other existing trading markets; 3.0% commission paid to Cowen.
- Offering made under prior S-3 registration statement; prospectus supplement filed February 27, 2024.
- No minimum sales required; Agent uses commercially reasonable efforts based on Company instructions.

## SEC filing metadata
- accession: 0001104659-24-027933
- form_type: 8-K
- cik: 0001773427
- company_name: SpringWorks Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773427/000110465924027933/0001104659-24-027933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773427/000110465924027933/tm247273d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-027933
- JSON: https://secwatch.observer/filing/0001104659-24-027933.json
- Plain text: https://secwatch.observer/filing/0001104659-24-027933.txt

## Key facts
- Material Agreements
  SpringWorks Therapeutics, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at $250 million (effective 2024-02-27).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: $250 million
  - Effective: 2024-02-27
  source text: On February 27, 2024, SpringWorks Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC, serving as sales agent (the “Agent”) with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $250 million (the “Shares”) through the Agent (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1773427/000110465924027933/0001104659-24-027933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.